EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models

Deepthi Ramesh-Kumar, Anaís Sánchez-Castillo, Marta Soler, Juan Francisco Martin-Tejera, Cristina Oliveira-Mateos, Veronica Davalos, Maria Martinez-Iniesta, Mar Martinez-Lozano, Monica Calaf, August Vidal, Alberto Villanueva, Sonia Guil und 1 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.116040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Deepthi Ramesh-Kumar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia 08916, Spain. Hauptthemen laut MEDLINE: Pseudogenes, Ovarian Neoplasms, Ribosomal Proteins, Oligonucleotides, Antisense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Carlos III Health Institute, European Regional Development Fund, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The RPSAP52 pseudogene is transcribed in the opposite direction to the oncofetal gene HMGA2 and is reexpressed in various human cancers. Here, we investigate the impact of RPSAP52 in ovarian cancer (OC) and explore the potential therapeutic application of GapmeR antisense oligonucleotides against RPSAP52 in preclinical models. RPSAP52 and HMGA2 expression were investigated in TCGA for OC and further explored in a panel of orthotopic PDXs and commercial cell lines by RT-qPCR. The Kaplan-Meier method was used to estimate survival associated with RPSAP52 expression in a dataset within the OC TCGA cohort. The effect of specific silencing of RPSAP52 on tumor growth in vitro and in vivo was evaluated by lentiviral-mediated depletion and antisense LNA GapmeRs against RPSAP52. The pseudogene RPSAP52 was overexpressed in epithelial OC in both patient samples and OC preclinical models coinciding with the overexpression of HMGA2. Elevated expression levels of RPSAP52 in the early stages of OC were associated with poorer clinical outcomes and could stratify patients in stages I and II. The specific depletion of RPSAP52 led to a reduction in OC tumor growth in vitro and in vivo. Furthermore, the treatment with antisense LNA GapmeRs against RPSAP52 showed significant antitumoral effect in OC cell lines and in a PDOX model (without evident toxicity). Our findings demonstrate that RPSAP52 displays pro-growth features in OC, underscoring the significance of pseudogenes in cancer pathophysiology. This pseudogene has potential utility as therapeutic target in OC and as valuable prognostic biomarker for the early stages of this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PseudogenesOvarian NeoplasmsRibosomal ProteinsOligonucleotides, AntisenseFemaleHumansAnimalsHMGA2 ProteinCell Line, TumorXenograft Model Antitumor AssaysMiceCell ProliferationGene Expression Regulation, NeoplasticMice, Nude

Stichwörter der Autor:innen

GapmeRsHMGA2Noncoding RNAOvarian cancerPDXRPSAP52 pseudogene

Substanzen

HMGA2 ProteinHMGA2 protein, humanRibosomal ProteinsOligonucleotides, Antisense

Autor:innen und Institutionen

  • Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia 08916, Spain.
  • Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. 616, Maastricht 6200 MD, the Netherlands.
  • Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Catal…
  • Pathology Department, Bellvitge Universitary Hospital, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
  • Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia 08916, Spain; Germans Trias i Pujol Health Science Research Institute, Badalona, Barcelona, Catalonia 08916, Spain. Electronic address: s…

Förderung

  • Carlos III Health Institute
  • European Regional Development Fund
  • Generalitat de Catalunya
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Ramesh-Kumar, D., Sánchez-Castillo, A., Soler, M., Martin-Tejera, J. F., Oliveira-Mateos, C., Davalos, V., Martinez-Iniesta, M., Martinez-Lozano, M., Calaf, M., Vidal, A., Villanueva, A., Guil, S., & Farre, L. (2025). Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116040

Vancouver

Ramesh-Kumar D, Sánchez-Castillo A, Soler M, Martin-Tejera JF, Oliveira-Mateos C, Davalos V, et al. Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.116040

BibTeX
@article{RameshKumar2025,
  author = {Ramesh-Kumar, Deepthi and Sánchez-Castillo, Anaís and Soler, Marta and Martin-Tejera, Juan Francisco and Oliveira-Mateos, Cristina and Davalos, Veronica and Martinez-Iniesta, Maria and Martinez-Lozano, Mar and Calaf, Monica and Vidal, August and Villanueva, Alberto and Guil, Sonia and Farre, Lourdes},
  title = {Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.116040}
}
Kostenlos starten →